The second most common cancer among men is prostate cancer, affecting 1 in 8 men. Prostate cancer is treatable, in most cases, when the cancer remains localized to the prostate gland. But if the ...

Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...

The American Cancer Society estimates that more than 313,780 cases of prostate cancer will be diagnosed in the United States in 2025, resulting in approximately 35,770 deaths. Bone metastasis - a ...

Rahul Parikh, MD, a professor of medicine at the University of Kansas (KU) Medical Center, discussed the critical role of ...

TTUHSC researcher Srinivas Nandana, Ph.D., (left) and co-investigator Manisha Tripathi, Ph.D., received a grant from the U.S. Department of Defense to investigate the role of TBX2 in establishing the ...

Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...

Justin Stebbing does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

Zoledronic acid reduced fracture risk by 27% in men with metastatic prostate cancer receiving ADT in the STAMPEDE trial. Patients with non-metastatic disease showed no significant fracture benefit ...

Add Yahoo as a preferred source to see more of our stories on Google. EDITOR’S NOTE: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the ...

Former President Joe Biden's office confirmed on Sunday that he was diagnosed with an "aggressive form" of prostate cancer. "Last week, President Joe Biden was seen for a new finding of a prostate ...